-
Ongericimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ongericimab Injection (trade name: 君适达/Junshida) of Shanghai Junshi Biosciences Co., Ltd. is approved for marketing by China NMPA.
-
Pradefovir Mesylate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Class 1 innovative drug Pradefovir Mesylate Tablets (trade name: 新舒沐) of Xi'an Gelan Xintong Pharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of adult patients with chronic hepatitis B, providing a new treatment option for patients.
-
Garsorasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Class 1 innovative drug Garsorasib Tablets (trade name: 安方宁) of Shanghai Chia-tai Tianqing Pharmaceutical Technology Development Co. Ltd. is approved with conditions for marketing through the priority review and approval procedure by NMPA in China.
-
Zorifertinib Hydrochloride Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Class 1 innovative drug Zorifertinib Hydrochloride Tablets (trade name: 泽瑞尼) of Alpha Biopharma (Jiangsu) Co., Ltd. is approved for marketing by China NMPA.
-
Renatus® Transcatheter Aortic Valve System Approved for Marketing
2025-02-19
Recently, the innovative product "Renatus® Transcatheter Aortic Valve System" of Beijing Balance Medical Technology Co., Ltd. is approved by China NMPA.
-
JETSTREAM™ PVCN100 Console and JETSTREAM™ Over-The-Wire Atherectomy Catheter Approved for Marketing
2025-02-19
Recently, the two innovative products "JETSTREAM™ PVCN100 Console" and "JETSTREAM™ Over-The-Wire Atherectomy Catheter" of Boston Scientific Corporation are approved by China NMPA.
